Quince Therapeutics, Inc. announced an update on its pivotal Phase 3 NEAT clinical trial for eDSP in Ataxia-Telangiectasia (A-T), reporting a total of 99 participants enrolled to date. This includes 78 participants in the six to nine year-old primary analysis population and 21 participants aged 10 years or older.
All 42 NEAT participants who have completed the double-blind portion of the study have elected to transition to the NEAT open-label extension (OLE) study, indicating continued patient and physician interest. This high transition rate is a positive sign for the drug's tolerability and perceived benefit.
The company also updated its timeline for topline results from the NEAT study, now expecting them in the first quarter of 2026, a slight adjustment from the previously anticipated fourth quarter of 2025. Assuming positive study results, Quince plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.